# Treeline Biosciences

Source: https://onco.cc/companies/treeline-biosciences/  
OnCo record `treeline-biosciences` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Treeline Biosciences is a well-funded private company building cancer drugs of several kinds, including a pill that blocks all forms of the KRAS cancer protein and drugs for lymphoma.

## Summary

Treeline Biosciences is a privately held, Watertown, Massachusetts biopharmaceutical company founded in 2021 that combines in-house inhibitor, protein degrader and antibody-drug conjugate capabilities with computational and machine-learning models. Its clinical programmes are TLN-121, a BCL6 degrader in phase 1 for B-cell and T-cell lymphomas; TLN-254, an EZH2 inhibitor (zeprumetostat, SHR2554) in-licensed from Jiangsu Hengrui for territories outside Greater China and in phase 1 in peripheral and cutaneous T-cell lymphoma; and TLN-372, a pan-KRAS inhibitor in phase 1 in solid tumours. Preclinical work extends to immunology and neurology. SEC Form D filings show more than 1 billion US dollars sold across private offerings between 2021 and 2025.

## Fields

- Kind: Company
- Last checked: 2026-09-10
- HQ: Watertown, MA
- Type: biotech
- Website: https://treeline.bio/

## Notes

- The domain treelinebio.com does not resolve; the company site is treeline.bio. Round names and investors are not disclosed in the Form D filings or on the site. The dlbcl tag is an approximation for 'B-cell and T-cell lymphomas'.

## Sources

- Official website: https://treeline.bio/
- Medicines (pipeline): https://treeline.bio/medicines
- Form D (September 2025): https://www.sec.gov/Archives/edgar/data/1856619/000185661925000002/primary_doc.xml

## Connected records

- cancers: [Diffuse large B-cell lymphoma](https://onco.cc/cancers/dlbcl/)
- fronts: [Epigenetic & Transcriptional Therapy](https://onco.cc/fronts/epigenetics/), [Targeted Therapy](https://onco.cc/fronts/targeted-therapy/)
- technologies: [AI-driven drug & target discovery](https://onco.cc/technologies/ai-drug-design/), [Epigenetic drugs (HDAC, DNMT, EZH2, IDH, menin, BET)](https://onco.cc/technologies/epigenetic-drugs/), [KRAS & RAS inhibitors](https://onco.cc/technologies/kras-inhibitors/), [PROTACs & molecular glues (targeted protein degradation)](https://onco.cc/technologies/protac-degrader/)
- targets: [EZH2](https://onco.cc/targets/ezh2/), [KRAS](https://onco.cc/targets/kras/)

---
JSON: https://onco.cc/api/v1/entities/treeline-biosciences.json